Jefferies Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $48
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Jefferies analyst Roger Song initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $48.
Jefferies analyst Roger Song initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $48.